S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.69 (-0.03%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.69 (-0.03%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.69 (-0.03%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.69 (-0.03%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
NASDAQ:NRSN

NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis

$1.80
+0.08 (+4.34%)
(As of 03:47 PM ET)
Today's Range
$1.73
$1.85
50-Day Range
$0.95
$2.11
52-Week Range
$0.40
$2.33
Volume
110,578 shs
Average Volume
297,796 shs
Market Capitalization
$24.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NRSN stock logo

About NeuroSense Therapeutics Stock (NASDAQ:NRSN)

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

NRSN Stock Price History

NRSN Stock News Headlines

NeuroSense Therapeutics Ltd NRSN
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
NeuroSense Says Phase 2b ALS Trial Meets Primary And Secondary Endpoints
NeuroSense Therapeutics GAAP EPS of -$0.67
NeuroSense Therapeutics 9-Month Loss Narrows
NeuroSense Therapeutics to Participate in BIO-Europe Fall
See More Headlines
Receive NRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NRSN
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Net Income
$-12,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.51 per share

Miscellaneous

Free Float
9,922,000
Market Cap
$23.65 million
Optionable
Not Optionable
Beta
1.61
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Alon Ben-Noon (Age 45)
    Co-Founder, CEO & Director
    Comp: $619k
  • Mr. Or Eisenberg (Age 43)
    Chief Financial Officer
    Comp: $378k
  • Dr. Ferenc Tracik M.D. (Age 60)
    Chief Medical Officer
    Comp: $513k
  • Ms. Hagit Binder (Age 46)
    Chief Operation Officer
  • Dr. Niva Russek-Blum Ph.D. (Age 45)
    Chief Technology Officer
  • Ms. Yael Barak (Age 54)
    VP of Quality & Compliance
  • Ms. Keren Pushett
    Head of HR
  • Mr. Eidan Loushi
    C.R.A.

NRSN Stock Analysis - Frequently Asked Questions

Should I buy or sell NeuroSense Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuroSense Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NRSN shares.
View NRSN analyst ratings
or view top-rated stocks.

How have NRSN shares performed in 2024?

NeuroSense Therapeutics' stock was trading at $0.7850 at the start of the year. Since then, NRSN shares have increased by 129.9% and is now trading at $1.8050.
View the best growth stocks for 2024 here
.

Are investors shorting NeuroSense Therapeutics?

NeuroSense Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 35,100 shares, a decrease of 83.4% from the February 29th total of 211,400 shares. Based on an average daily volume of 286,100 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.4% of the company's stock are sold short.
View NeuroSense Therapeutics' Short Interest
.

When is NeuroSense Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Saturday, May 25th 2024.
View our NRSN earnings forecast
.

When did NeuroSense Therapeutics IPO?

NeuroSense Therapeutics (NRSN) raised $13 million in an IPO on Thursday, December 9th 2021. The company issued 2,000,000 shares at a price of $6.00-$7.00 per share.

How do I buy shares of NeuroSense Therapeutics?

Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRSN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners